title: HPV-induced recurrent laryngeal papillomatosis: rationale for adjuvant fatty acid therapy.
abstract: The course of human papilloma virus (HPV)-induced recurrent laryngeal papillomatosis (RLP) is variable and unpredictable. Some patients experience spontaneous remission, while others suffer from aggressive growth with dire consequences. Unfortunately, HPV DNA can persist in mucosa after treatment and can be reactivated under immunosuppressive conditions. For this reason, these benign tumors are notoriously recurrent. Better understanding of lipid-driven signaling pathways during tumorigenesis and immune responses in RLP patients can contribute to improve therapeutic approaches in an attempt to obviate this disease. Based on a mountain of evidence in the literature that concerns the immunomodulatory potential of certain FAs, it is clear that there is a rationale for adjuvant FA therapy (concurrent application) in the management of RLP. Of particular importance for immune surveillance is that the Th1 pathway in RLP is down-regulated and it is advocated that conjugated linoleic acid (CLA) and eicosapentaenoic acid (EPA) have the ability to restore the Th1/Th2 balance. Therefore, it is proposed that adjuvant FA therapy with CLA and EPA must be included in the therapeutical regime of RLP, since they are considered excellent anti-viral and anti-tumor agents to improve immune conditions and disease outcome. Immunocompetence plays a pivotal role in the clinical course of RLP and, hence, a new direction with adjuvant FA therapy may be the key to prevent recurrence of this disease.
authors.affiliation: Department of Otorhinolaryngology, University of the Free State, Bloemfontein, South Africa. gnanll.md@mail.ufs.ac.za
authors.forename: Louise
authors.initials: L
authors.lastname: Louw
authors.forename: André
authors.initials: A
authors.lastname: Claassen
mesh_terms: D000917:Antibody Formation / Q000276:immunology; D017024:Chemotherapy, Adjuvant; D005227:Fatty Acids / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D010212:Papilloma / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D005227:Fatty Acids